» Articles » PMID: 38779567

Gut Microbiota Microbial Metabolites in Diabetic Nephropathy Patients: Far to Go

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic nephropathy (DN) is one of the main complications of diabetes and a major cause of end-stage renal disease, which has a severe impact on the quality of life of patients. Strict control of blood sugar and blood pressure, including the use of renin-angiotensin-aldosterone system inhibitors, can delay the progression of diabetic nephropathy but cannot prevent it from eventually developing into end-stage renal disease. In recent years, many studies have shown a close relationship between gut microbiota imbalance and the occurrence and development of DN. This review discusses the latest research findings on the correlation between gut microbiota and microbial metabolites in DN, including the manifestations of the gut microbiota and microbial metabolites in DN patients, the application of the gut microbiota and microbial metabolites in the diagnosis of DN, their role in disease progression, and so on, to elucidate the role of the gut microbiota and microbial metabolites in the occurrence and prevention of DN and provide a theoretical basis and methods for clinical diagnosis and treatment.

Citing Articles

Diphenyl diselenide protects against diabetic kidney disease through modulating gut microbiota dysbiosis in streptozotocin-induced diabetic rats.

Wang X, Long D, Peng X, Li J, Zhou M, Wang Y Front Pharmacol. 2024; 15:1506398.

PMID: 39697537 PMC: 11653185. DOI: 10.3389/fphar.2024.1506398.

References
1.
Xu J, Ma C, Hua M, Li J, Xiang Z, Wu J . CNS and CNS diseases in relation to their immune system. Front Immunol. 2022; 13:1063928. PMC: 9708890. DOI: 10.3389/fimmu.2022.1063928. View

2.
Chen L, Shi J, Ma X, Shi D, Qu H . Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2021; 13(4):1267-1278. PMC: 9340978. DOI: 10.1093/advances/nmab149. View

3.
Zhu H, Bai M, Xie X, Wang J, Weng C, Dai H . Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus. Nutrients. 2022; 14(16). PMC: 9415588. DOI: 10.3390/nu14163345. View

4.
Winther S, Henriksen P, Vogt J, Hansen T, Ahonen L, Suvitaival T . Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria. Diabetologia. 2020; 63(12):2713-2724. DOI: 10.1007/s00125-020-05260-y. View

5.
Salguero M, Al-Obaide M, Singh R, Siepmann T, Vasylyeva T . Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease. Exp Ther Med. 2019; 18(5):3461-3469. PMC: 6777309. DOI: 10.3892/etm.2019.7943. View